All In Biotech

Drug Trial Radar · NCT00659425

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Sep 2008

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Apr 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.

Conditions

  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma

Interventions

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

  • CAT-8015 (Moxetumomab Pasudotox)Drug

    Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Day 1 up to 21 days of Cycle 1 (each cycle duration was of 21 days)
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From start of study drug administration until 30 days after the last dose of study drug
  3. Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of study drug administration until 30 days after the last dose of study drug
  4. Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to 30 days after the last dose of study drug
  5. Treatment-Emergent Adverse Events (TEAEs) Related to Chemistry Abnormalities Occurring in Greater Than (>) 5 Percent of ParticipantsTime frame: From start of study drug administration up to 30 days after the last dose of study drug
  6. Number of Participants With Abnormalities in Ophthalmologic Examination at End of Treatment That Were Not Present at BaselineTime frame: Baseline and end of treatment (up to 1 year after the last participants begins study drug treatment)
  7. Number of Participants With Change From Baseline in Normal Sinus Rhythm Findings in ECGTime frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment)
  8. Change From Baseline to End of Treatment in Clinical Findings in Electrocardiogram (ECG) QT, QTC Interval and Ventricular RateTime frame: Baseline and end of treatment (up to 1 year after the last participants begins study drug treatment)
  9. Best Overall Tumor ResponseTime frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment)
  10. Objective Response Rate (ORR)Time frame: Baseline until end of treatment (up to 1 year after the last participant begins study drug treatment)
  11. Percentage of Participants With Relapse of DiseaseTime frame: Baseline until end of treatment (up to 1 year after the last participant begins study drug treatment)
  12. Time to Disease ResponseTime frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment)
  13. Duration of Response (DR)Time frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment
  14. Time to Disease Progression (TDP)Time frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment
  15. Progression-Free Survival (PFS)Time frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment)
  16. Overall Survival (OS)Time frame: Baseline and end of treatment (up to 1 year after the last participant begins study drug treatment)
  17. Maximum Observed Serum Concentration (Cmax) for Moxetumomab PasudotoxTime frame: Cycles 1, 2 and every 4th cycle: pre-dose, end of infusion (EOI), 1, 1.5, 2.5, 4 and 8 hours post-dose of Dose 1; pre-dose and end of infusion after Dose 6
  18. Area Under the Serum Concentration Time Curve From Time Zero to Infinity (AUC [0 to Infinity]) for Moxetumomab PasudotoxTime frame: Cycles 1, 2 and every 4th cycle: pre-dose, end of infusion (EOI), 1, 1.5, 2.5, 4 and 8 hours post-dose of Dose 1; pre-dose and end of infusion after Dose 6
  19. Systemic Clearance (CL) for Moxetumomab PasudotoxTime frame: Cycles 1, 2 and every 4th cycle: pre-dose, end of infusion (EOI), 1, 1.5, 2.5, 4 and 8 hours post-dose of Dose 1; pre-dose and end of infusion after Dose 6
  20. Terminal Phase Elimination Half Life (t1/2) for Moxetumomab PasudotoxTime frame: Cycles 1, 2 and every 4th cycle: pre-dose, end of infusion (EOI), 1, 1.5, 2.5, 4 and 8 hours post-dose of Dose 1; pre-dose and end of infusion after Dose 6

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Bethesda, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Memphis, Tennessee

  • Research Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.